A U.S. cannabis company has expressed interest in acquiring Aurora Cannabis Inc., prompting the Edmonton-based firm to form a special committee to evaluate the unsolicited bid. Curaleaf Holdings Inc., based in Stamford, Conn., disclosed its intention to acquire all shares of Aurora, aiming to create a global cannabis entity spanning 17 countries. Despite attempts to privately negotiate with Aurora, Curaleaf decided to publicly announce its proposal after facing reluctance from Aurora’s board. Curaleaf’s CEO, Boris Jordan, expressed disappointment over Aurora’s lack of engagement and emphasized the strategic benefits of the merger.
Curaleaf proposed a payment of $4 US per share to Aurora shareholders, along with an additional $0.75 US in cash for each share. Aurora acknowledged receiving letters from Curaleaf outlining acquisition proposals but contested Curaleaf’s claim that Aurora refused to discuss the offer. Aurora clarified that discussions with Curaleaf’s CEO had occurred recently, indicating a willingness to explore potential opportunities.
Aurora intends to convene an independent committee to assess the bid’s viability and alignment with stakeholders’ interests. However, the company cautioned that a deal is not guaranteed, emphasizing its commitment to normal operations in the interim. Despite TD Cowen analysts questioning the valuation offered by Curaleaf, the potential merger is viewed as a means to leverage Curaleaf’s global network and Aurora’s medical cannabis expertise to drive mutual growth.
The combined revenue of the two companies exceeded $1.5 billion US in the past year, with Curaleaf anticipating annual cost synergies of at least $40 million US post-acquisition. Jordan highlighted the value in merging the companies, underscoring the opportunity for Aurora shareholders to access a diversified global platform and capitalize on regulatory trends in the U.S. cannabis market.
